Abstract
Type 1 diabetes, insulin-dependent diabetes mellitus (IDDM) is a T-cell-mediated autoimmune disease (Bach 1994). It is thus logical to attempt to stop or better prevent disease progression by immunotherapy. A multitude of immunological treatments have been shown to be successful in the most currently available model of type 1 diabetes, namely, the nonobese diabetic (NOD) mouse. This observation may be taken in a positive fashion, paving the way for testing these strategies in humans. Conversely, one may wonder whether the NOD mouse is not, in some ways, “too sensitive” to immunological intervention, rendering the extrapolation of results obtained in NOD mice to human diabetes uncertain. This is, in fact, a very complex question which shall be addressed in some detail below.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bach J-F (1994) Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Rev 15: 516–542
Bach J-F (1998) The natural history of islet-specific autoimmunity in NOD mice. In: Leiter E, Atkinson M (eds) NOD mice and related strains: research applications in diabetes, AIDS, cancer and other diseases. RG Landes, Austin, Tex, pp 121–144
Bach J-F (2001) Protective role of infections and vaccinations on autoimmune diseases. J Autoimmun 16: 347–353
Bach J-F, Chatenoud L (2001) Tolerance to islet autoantigens and type I diabetes. Annu Rev Immunol 19: 131–161
Bertry-Coussot L, Lucas B, Danel Claire, Halbwachs-Mecarelli L, Bach J-F, Chatenoud L, Lemarchand P (2002) Long-term reversal of established autoimmunity upon transient blockade of the LFA-1/intercellular adhesion molecule-1 pathway. J Immunol 168: 3641–3648
Canadian-European Randomized Control Trial Group (1988) Cyclosporin-induced remission of IDDM after early intervention: association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37: 1574–1582
Chatenoud L, Thervet E, Primo J, Bach J-F (1994) Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 91: 123–127
Diabetes Prevention Trial-Type 1 Diabetes Study Group (2002) Effects of insulin in relatives of patients with type 1 diabetes mellitu. N Engl J Med 346: 1685–1691
Elias D, Cohen IR (1994) Peptide therapy for diabetes in NOD mice. Lancet 343: 704–706
Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Yexiau P, Du Rostu H, Rodier M, Sirmai J, Lallemand A, Bach J-F (1986) Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset: results of a multicentre double-blind trial. Lancet 2: 119–124
Herold KC, Hagopian W, Auger J A, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346: 1692–1698
Kim JY, Cho SH, Kim YW, Jang EC, Park SY, Kim EJ, Lee SK (1999) Effects of BCG, lymphotoxin and bee venom on insulitis and development of IDDM in non-obese diabetic mice. J Kor Med Sci 14: 648–652
Lampeter EF, Klinghammer A, Scherbaum WA, Heinze E, Haastert B, Giani G, Kolb H (1998) The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes: DENIS Group. Diabetes 47: 980–984
Liang L, Beshay E, Prud’Homme GJ (1998) The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. Diabetes 47: 570–575
Maki T, Ichikawa T, Blanco R, Porter J (1992) Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Natl Acad Sci USA 89: 3434–3438
Miller BJ, Appel MC, O’Neil JJ, Wicker LS (1988) Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J Immunol 140: 52–58
Pozzilli P, Visalli N, Ghirlanda G, Manna R, Andreani D (1989) Nicotinamide increases C-peptide secretion in patients with recent onset type 1 diabetes. Diabet Med 6: 568–572
Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR (2001) Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358: 1749–1753
Silverstein J, MacLaren N, Riley W, Spillar R, Radjenovic D, Johnson S (1988) Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 319: 599–604
Toyota T, Satoh J, Oya K, Shintani S, Okano T (1986) Streptococcal preparation (OK-432) inhibits development of type I diabetes in NOD mice. Diabetes 35: 496–499
Wang Y, Hao L, Gill RG, Lafferty KJ (1987) Autoimmune diabetes in NOD mouse is L3T4 T-lymphocyte dependent. Diabetes 36: 535–538
Yasunami R, Bach J-F (1988) Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur J Immunol 18: 481–484
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Wien
About this chapter
Cite this chapter
Bach, JF. (2003). On the extrapolation from animal models to human disease for the design of immunotherapy in autoimmune diabetes. In: Sticherling, M., Christophers, E. (eds) Treatment of Autoimmune Disorders. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6016-9_2
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6016-9_2
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-7288-9
Online ISBN: 978-3-7091-6016-9
eBook Packages: Springer Book Archive